| Literature DB >> 29635872 |
Natalia Zidan1, Cory Sims1, Joe Fenn2, Kim Williams1, Emily Griffith3, Peter J Early1, Chris L Mariani1,4, Karen R Munana1,4, Julien Guevar1, Natasha J Olby1,4.
Abstract
BACKGROUND: Experimental evidence shows benefit of rehabilitation after spinal cord injury (SCI) but there are limited objective data on the effect of rehabilitation on recovery of dogs after surgery for acute thoracolumbar intervertebral disc herniations (TL-IVDH).Entities:
Keywords: ataxia; gait training; locomotion; plasticity; spinal cord injury
Mesh:
Year: 2018 PMID: 29635872 PMCID: PMC5980307 DOI: 10.1111/jvim.15086
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
Drugs used postoperatively for pain and anxiety control and to facilitate bladder expression
| Drug | Dose/route | Frequency | Duration | Reason |
|---|---|---|---|---|
| Hydromorphone | 0.05‐0.1 mg/kg IV | Q8h | 24 hours | Pain control |
| Carprofen | 2.2 mg/kg PO | Q12h | 7 days | Pain control |
| Meloxicam | 0.1 mg/kg PO | Q24h | 7 days | Pain control |
| Fentanyl | 3–5 μg/kg/h Transdermal | Continuous release | 5 days | Pain control |
| Gabapentin | 10 mg/kg PO | Q8h | 10 days | Pain control |
| Phenoxybenzamine | 0.5 mg/kg PO | Q12h | As needed | Bladder expression |
| Prazosin | 1–2 mg/dog PO | Q8–12h | As needed | Bladder expression |
| Diazepam | 0.5 mg/kg PO | Q8h 20 min before bladder expression | As needed | Bladder expression |
| Trazodone | 2–8 mg/kg PO | Q8–12h | As needed | Anxiety |
Abbreviations: d, day; h, hour; IV, intravenous; min: minutes; PO, per os.
a Hydromorphone: West Ward Pharmaceutics, Eatontown, New Jersey
b Carprofen: Rimadyl, Zoetis, Lincoln, Nebraska
c The nonsteroidal anti‐inflammatory drug (NSAID) choice was influenced by which NSAID had been administered before referral. If dogs were receiving corticosteroids before admission, omeprazoleh (1 mg/kg, PO, q24h) and prednisonei in a tapering course were substituted for the NSAID.
d Meloxicam: Metacam, Boehringer Ingelheim, St Joseph, Missouri
e Fentanyl transdermal patch, Mylan, Morgantown, West Virginia
f Gabapentin: Method, Fort Worth, Texas
g Dogs were placed on phenoxybenzamine if they were unable to urinate. If their bladder could not be expressed readily after 48 hours on this drug prazosin was substituted.
h Phenoxybenzamine: compounded by NCSU VH Pharmacy, Raleigh, North Carolina
i Prazosin: Mylan, Morgantown, West Virginia
j Diazepam: Mylan, Rockford, Illinois
k Trazodone: TEVA, North Wales, Pennsylvania
Figure 1Diagram depicting the rehabilitation protocols and how they evolved over time. Day 1 is day of entry into the trial. PROM, passive range of motion; NMES, neuromuscular electrical stimulation
Figure 2CONSORT flow diagram of the clinical trial. Of the 14 dogs with a change in neurologic status, 2 dogs deteriorated and lost pain perception in their pelvic limbs and 12 dogs improved to take some weight bearing steps
Comparison of demographics and clinical history, and findings at trial entry
| Variable | Basic protocol | Intensive protocol |
| |
|---|---|---|---|---|
| Breed: Dachshund; Other | 10 Dachshunds | 7 Dachshunds |
| |
| 5 Other | 8 Other | |||
| Age (years) Mean (SD) | 6 (2.25) | 5.4 (2.5) |
| |
| Sex | 9 M, 5 FS, 1 F | 2 M, 7 MC, 6 FS | ||
| BCS, median (range) | 6 (4–8) | 5 (2–6) |
| |
| Body weight, median (range) | 7.4 (4.3–13.9) | 7.6 (2.8–14.5) |
| |
| Duration of nonambulatory status (dogs) | <12 hours | 1 | 1 |
|
| 12–24 hours | 7 | 5 | ||
| 24–48 hours | 4 | 6 | ||
| 48–72 hours | 3 | 3 | ||
| Neurologic status preoperative/Day 1 of trial | Nonambulatory paraparetic | 8/9 | 11/9 |
|
| Paraplegic | 7/6 | 4/6 | ||
| Imaging modality | MRI: 8; CT: 7 | MRI:11; CT:4 | NA | |
| Number of hemilaminectomy sites, median (range) | 1 (1–4) | 1 (1–3) |
| |
Other breeds included American Cocker Spaniel, mixed breed, Chihuahua, Corgi, Havanese, and Shih Tzu.
Abbreviations: BCS, body condition score; CT, computed tomography; F, female; FS, female spayed; M, male; MC, male castrated; MRI, magnetic resonance imaging; OFS, open field score.
Figure 3The number of dogs with intervertebral disc herniations at different locations in each group. T: thoracic; L: lumbar
Primary outcome measures
| Group | OFS mean (SE) | 95% CI | RI mean (SE) | 95% CI | |
|---|---|---|---|---|---|
| Basic (n = 15) | Day 1 | 1.73 (0.48) | 0.70‐2.77 | 0 (0) | NA |
| Day 14 | 7.87 (0.61) | 6.56‐9.17 | 55.13 (8.51) | 36.88‐73.38 | |
| Change | 6.13 (0.58) | 4.88‐7.39 | NA | NA | |
| Intensive (n = 15) | Day 1 | 2 (0.47) | 1.0–3.0 | 0 (0) | NA |
| Day 14 | 7.73 (0.4) | 6.88‐8.58 | 51.65 (9.64) | 30.98‐72.33 | |
| Change | 5.73 (0.37) | 4.94‐6.53 | NA | NA |
Abbreviations: CI, confidence interval; OFS, open field score; RI, regulatory index; SE, standard error.
GCPS score in dogs at each time point in each treatment group
| Basic protocol | Intensive protocol | ||
|---|---|---|---|
| Time points | Median (range) | Median (range) |
|
| Day 1 | 4 (0–9) | 2 (0–8) | .14 |
| Day 3 | 2 (0–7) | 1 (0–5) | .46 |
| Day 7 | 1 (0–4) | 0 (0–6) | .49 |
| Day 14 | 0.56 (0–1) | 0 (0–4) | .60 |
| Day 28 | 0 (0–2) | 0 (0–1) | .22 |
| Day 42 | 0 (0–1) | 0 (0–1) | .26 |
Secondary outcome measures
| Basic protocol | Intensive protocol | |||||
|---|---|---|---|---|---|---|
| Variable |
| Median (range) |
| Median (range) |
| |
| Time to walking (D) | 15 | 5 (2–37) | 15 | 8 (3–15) | .46 | |
| OFS change D42‐D1 | 15 | 8 (3–11) | 14 | 7 (5–10) | .69 | |
| RI D42 | 15 | 80.95 (23.1–100) | 14 | 82 (25.4–98) | .84 | |
| PP D14 | 15 | 1 (0–4) | 15 | 1 (0–4) | .98 | |
| PP D42 | 15 | 3 (0–4) | 14 | 3 (0–4) | .98 | |
| L thigh circ change | D1–14 | 15 | 0.1 (–0.2‐0.7) | 15 | 0.3 (–0.7‐1) | .24 |
| D14–42 | 15 | −0.1 (–1.8‐1.2) | 14 | −0.15 (–1.5‐0.4) | .45 | |
| D1–42 | 15 | 0 (–1.8‐1.7) | 14 | 0 (–1.4‐1.4) | .91 | |
| R thigh circ change | D1–14 | 15 | 0.2 (–0.4‐0.8) | 15 | 0.2 (–0.7‐1.1) | .35 |
| D14–42 | 15 | −0.1 (–1.8‐1.2) | 14 | −0.15 (–1.5‐0.4) | .73 | |
| D1–42 | 15 | −0.1 (–1.1‐1.6) | 14 | −0.05 (–1.1‐1.5) | .73 | |
| Weight change | D1–14 | 15 | 0.5 (–0.6‐1.2) | 15 | 0.4 (–1‐1) | .50 |
| D14–42 | 15 | −0.3 (–1.7‐1.1) | 14 | 0 (–0.5‐0.8) | .25 | |
| D1–42 | 15 | 0.3 (–0.6‐0.9) | 14 | 0.45 (–0.4‐1.4) | .63 | |
Abbreviations: circ, circumference; D, day; L, left; OFS, open field score; PP, proprioceptive placing; R, right; RI, regularity index.
Summary of the adverse events recorded in both groups
| Adverse event | Basic protocol | Intensive protocol |
|---|---|---|
| Bacteriuria |
|
|
|
| ||
| GI signs | Transient vomiting (n = 2) Week 1 | Regurgitation Week 1 (n = 2) |
| Diarrhea Week 1 (n = 1) | ||
| Inappetant days 1–5 (n = 1) | ||
| Superficial pyoderma | At presentation (n = 1) | |
| Hematuria | Week 1 (n = 1). Sterile urine culture | |
| Fever | Week 1, unknown origin (n = 1) | |
| Seroma | Week 2–4 (n = 1) |
Abbreviation: GI: gastrointestinal.
Adverse events in all dogs were resolved with appropriate treatment.